1801: Innovent Biologics, Inc. - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

Innovent Biologics, Inc.

HKG:1801

SummaryFactSheetFinancial
Price
HK$96.25
Loss Chance
47.6%
5.27JITTA SCORE
146.20%Over Jitta Line
Jitta Ranking
Biotechnology
11 / 64
Health Care
51 / 241
Hong Kong
?
441 / 2,586
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Related
3SBio
HKG:1530
7.67
HK$15.85
80.07%
Everest Medicines Limited
HKG:1952
4.91
HK$28.64
1.06%
Mabpharm Limited
HKG:2181
4.91
HK$0.49
75.48%
Mabpharm Limited
HKG:2181
4.91
HK$0.49
75.48%
Qyuns Therapeutics Co., Ltd.
HKG:2509
3.71
HK$17.00
62.25%
Jitta Factors
Growth Opportunity (65)
Recent Business Performance (63)
Financial Strength (78)
Return to Shareholders (0)
Competitive Advantage (56)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
SG&A to SalesDecreasing Every Year
Revenue and EarningEarning loss detected in 2023
Key Stats
Jitta Score
Jitta Line
5.27
146.20%
3.08
957.99%
3.80
412.99%
Biotechnology
7.67
80.07%
4.91
1.06%
4.91
75.48%
COMPANY DESCRIPTION
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverembatinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), DUPERT (fulzerasib), DOVBLERON (taletrectinib adipate), Jaypirca (pirtobrutinib), limertinib, SYCUME (teprotumumab N01 injection), mazdutide, PECONDLE (picankibart injection), and TABOSUN(Ipilimumab N01 injection). In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People’s Republic of China.
www.innoventbio.com
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.